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Abstract
Background: Promoting and supporting smoking reduction in smokers with no immediate intention of stopping
smoking is controversial given existing fears that this will deter cessation and that reduction itself may not improve
health outcomes.
Discussion: Evidence shows that smokers who reduce the number of daily cigarettes smoked are more likely to
attempt and actually achieve smoking cessation. Further, clinical trials have shown that nicotine replacement therapy
benefits both reduction and cessation. Worldwide data suggests that ‘non-medical’ nicotine is more attractive to people
who smoke, with electronic cigarettes now being widely used. Nevertheless, only one small trial has examined the use
of electronic cigarettes to promote reduction, with direct evidence remaining inconclusive. It has been suggested that
long-term reduced smoking may directly benefit health, although the benefits are small compared with cessation.
Summary: The combined data imply that smoking reduction is a promising intervention, particularly when supported
by clean nicotine; however, the benefits are only observed when it leads to permanent cessation.
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Background
Smoking reduction, defined herein as a decrease in the
number of cigarettes smoked per day, is a strategy used
by smokers to moderate the health and financial effects
of smoking and ease towards complete cessation [1]. It
is advocated by some health professionals for smokers
who have no immediate intention of quitting or those
who have been unable to do so. Despite approximately
half of all smokers in England currently attempting a re-
duction in smoking [2], this strategy remains controver-
sial. Concerns have been raised regarding smoking
reduction being seen as a favourable alternative com-
pared to complete cessation, thus possibly decreasing
the likelihood of future cessation [3]. Nevertheless, even-
tual cessation success may be influenced by the methods
used to reduce smoking, particularly given the several
options currently available to support this, including
pharmacotherapies, such as nicotine replacement therapy
(NRT) or varenicline, oral tobacco products including
snus, and more recently, novel devices such as electronic
cigarettes (e-cigarettes). However, if smokers are unable to
quit following reduction, it is important to understand
whether this affects their health outcomes in order to in-
form the current debate.
In this opinion piece, the main issues related to smoking
reduction and cessation are considered and evaluated
based on the available evidence. The discussion includes
an evaluation of whether promoting smoking reduction
directly or indirectly deters cessation, a summary of the
methods available to reduce smoking, and discussion of
evidence that reduction itself may decrease the harm from
smoking even if cessation is not achieved.
Reduction may lead to complete cessation
Several theoretical factors indicate that smoking reduc-
tion promotes rather than deters cessation. Firstly,
smoking reduction may be a more attainable goal com-
pared to complete cessation and is more desirable than
regular smoking; additionally, once achieved, it may en-
courage further efforts to achieve cessation (Michie S,
Personal communication). Further, regular smoking results
in neuroadaptation, which manifests in the features recog-
nised as tobacco addiction [4]; smoking reduction could
reverse these adaptations and decrease the severity of
withdrawal and cravings when smokers abstain altogether.
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Indeed, withdrawal effects and cravings are the main
barriers to achieving cessation and contributing to re-
lapse [5]. The neural processes induced by cigarette
smoking lead to the formation of conditioned rela-
tionships between environmental stimuli and smoking.
A reduction in smoking may disrupt these relation-
ships so that a desire to smoke is less likely to be
triggered by previous cues to do so [4]. Another hy-
pothesis concerns ‘shaping’, which involves making
successive, positively reinforced approximations of a
target behaviour, thus encouraging the desired final
behaviour [6]. In the context of smoking, gradually
reducing the number of daily cigarettes may induce
intermittent reinforcement, offering encouragement to
and increasing the likelihood of quitting altogether.
Finally, the positive reinforcement that smokers may
experience when gradually reducing the number of ciga-
rettes smoked could also increase their self-efficacy – an
individual’s belief in their ability to succeed. Increases in
self-efficacy are thought to heighten the likelihood that a
final goal – in this case cessation – will be achieved [7].
Despite all of the above factors being merely hypothet-
ical, there is evidence of an association between smoking
reduction and subsequent cessation. A telephone survey
of 1,000 daily smokers in the US suggested that most of
those who reduced their smoking did so as a stepping
stone to cessation [8]. A qualitative systematic review,
including 19 observational studies (smokers who had
spontaneously reduced smoking or not) or randomised
controlled trials (RCTs; smokers instructed to reduce
smoking or not) reporting on changes in the number of
cigarettes smoked per day and future cessation, showed
no indication that reduction adversely affected the rate
of future quitting [9]. Indeed, 16 of the included studies
indicated that reduction was associated with higher rates
of eventual cessation. These findings are supported by a
later review of 10 RCTs, in which all of the included tri-
als compared either a pharmacological, behavioural, or
combined smoking reduction intervention in smokers
not yet ready to quit to at least one control group, de-
fined as placebo, no treatment, or minimal psychological
intervention [10]. Meta-analysis of the pharmacological
and combined interventions showed that both reduction
interventions increased the likelihood of long-term ab-
stinence (6 months or over). Nevertheless, there was
insufficient evidence available to reach a conclusion on
whether behavioural support for reduction alone en-
hanced future cessation. A key methodological issue
with these reviews is that most reduction studies only
report 7-day, point-prevalence smoking abstinence at
the end of follow-up, which will overestimate long-term
cessation. Future studies should follow published recom-
mendations for measuring abstinence in trials of smokers
who are not ready to quit [11].
Supporting smoking reduction and subsequent cessation
The aim of smoking reduction is to decrease the ex-
posure to tobacco toxins and facilitate subsequent
cessation. However, evidence suggests that smokers
involuntarily undermine their best intentions by com-
pensating, namely adjusting the way they smoke, for
example, by taking longer, deeper puffs to maintain
the same levels of nicotine [12]. Switching to alterna-
tive, less hazardous sources of nicotine while smoking
fewer cigarettes may limit the extent of compensation
and perhaps reduce the harm of smoking.
Results from several RCTs have demonstrated that
smokers who are unmotivated to quit are more likely to
reduce their cigarette consumption when using NRT
compared with placebo [13]. Many countries have li-
cenced the use of NRT for the purpose of reducing
smoking and eventually quitting. NRT is intermittently
promoted for this use, with the UK promoting harm re-
duction as national policy, but is not implemented in the
UK as it is in RCTs, where participants have regular
support and supervision. UK population data suggests
that using NRT to reduce smoking is not associated
with lower cigarette consumption relative to reduction
without NRT [14]. However, it is associated with in-
creased motivation to quit and higher cessation rates
[15, 16].
Results from other countries suggest that non-medical
forms of nicotine may be more popular. Smokeless to-
bacco is another non-combustible source of nicotine.
Although it is more hazardous than NRT, some oral to-
bacco products, such as Swedish snus, have been esti-
mated to be approximately 90 % less harmful than
smoking [17]. In Sweden, a reduction in smoking among
men has been attributed to substituting cigarettes with
snus, leading to lower tobacco-related mortality rates
than in other European countries [18]. Cross-sectional
surveys show that snus use is associated with smoking
reduction and a higher probability of cessation [19–21].
Some RCTs report on the potential benefits of smokeless
tobacco, a non-combustible source of nicotine, on in-
creasing cessation rates in motivated smokers [22, 23],
but there are only few comparable trials in smokers who
have no intention of quitting. In one pilot study, 31 non-
motivated smokers were randomised to receive smoke-
less tobacco lozenges or to continue smoking cigarettes
[24]. Smokeless tobacco use led to significant reductions
in smoking and significant increases in two measures of
readiness to quit, while no such changes were found in
those randomised to continue smoking. Similarly, an-
other pilot study found that those randomised to receive
snus reported a reduction in the number of cigarettes
smoked per day and greater intention to quit smoking
compared with a no-supply control group [25]. However,
these findings are preliminary and larger studies are
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needed to examine whether these interventions do in-
deed increase cessation rates.
The use of e-cigarettes by regular smokers has been
increasing worldwide [26, 27]. Nevertheless, evidence in-
dicating that they are effective in encouraging and sup-
porting smoking reduction and cessation is limited.
Despite these being termed cigarettes, they do not con-
tain tobacco and there is no combustion involved; the
nicotine included in e-cigarettes is extracted from to-
bacco and toxicological testing of the vapour reveals
high traces of tobacco toxins, exceeding those in NRT,
but at concentrations much lower than those in conven-
tional cigarettes [28]. A report commissioned by the
World Health Organization [29] and a subsequent re-
view [30] concluded that the health benefits and efficacy
of e-cigarettes for harm reduction and cessation were
unsupported by the evidence to date, although this has
been contested [31]. Data from clinical studies show no
adverse effects of their short-term use on cardiovascular
function [32]. More trials and studies are needed, par-
ticularly with regards to long-term risks. Survey data
show that e-cigarettes are most commonly used in the
reduction and cessation of cigarette consumption, to al-
leviate tobacco withdrawal symptoms, and to reduce the
harm associated with smoking [33, 34]. Findings from a
recent Cochrane review of two RCTs suggest that e-
cigarettes with nicotine help smokers to reduce their
cigarette consumption and quit compared to placebo
[35]. One of the included studies examined the effects of
e-cigarette use in smokers not intending to quit, com-
paring two different e-cigarette nicotine doses with pla-
cebo e-cigarettes [36]. The authors found that, at 1 year,
more smokers in the nicotine e-cigarette groups were
able to reduce their cigarette consumption by at least
half and quit compared with the placebo group, though
these differences were not statistically significant. Des-
pite the fact that the study was underpowered to detect
differences in cessation between groups and used products
with low nicotine delivery, the data suggests that e-
cigarettes may help those unable to quit to reduce smok-
ing and eventually do so. This is also supported by the
findings of prospective cohort studies [37–40].
The effectiveness of e-cigarettes in promoting smoking
cessation in current smokers may also depend on the
type of e-cigarettes used and the frequency of use [41, 42].
A recent survey found that, compared with non-use, daily
use of e-cigarettes while smoking was associated with in-
creased cessation attempts and reduced smoking, but not
with final cessation [41]. Hitchman et al. [42] found that
daily users of the tank model of e-cigarettes were more
likely to have quit at the 1-year follow-up compared with
those who reported no use, while non-daily users of e-
cigarettes that mimic cigarettes, cigalikes, were less likely
to have quit. It is clear that e-cigarette devices are evolving
rapidly, gradually becoming more effective in promoting
smoking reduction and cessation.
Can smoking reduction without cessation benefit health?
The prime reason for smokers to reduce or quit smoking
is to mitigate the health harms [43]. Smoking causes
three main fatal conditions – ischaemic heart disease,
lung cancer, and chronic obstructive pulmonary disease
(COPD). For each of these conditions, there is a clear
dose–response relationship between smoking level and
risk of developing or dying from the disease [44–46]. It
stands to reason that reduced smoking would mitigate
some of the harms, particularly for COPD and lung can-
cer, where the dose–response relationship is steep. There
is epidemiological evidence that supports this reasoning
to some extent. In 2007, a systematic review indicated
that only one study reported no reduction in the risk of
myocardial infarction over 15 years, following a reduction
of at least one-half of the initial cigarette consumption
[47]. A subsequent study showed evidence that smoking
reduction decreased cardiovascular disease rates, report-
ing a hazard ratio (HR) of reducers over maintainers of
0.77 (95 % confidence interval (CI), 0.66–0.94) [48]. Simi-
larly, another large cohort study produced data that sug-
gested, but did not conclusively show, a reduced risk of
infarction and stroke in reducers [49]. A study examining
outcomes in peripheral vascular disease showed a reduced
risk of progression [47]. Likewise, studies with short
follow-up generally showed an improvement in cardiovas-
cular risk factors in response to reduced smoking [47].
Nevertheless, a combined analyses of two Scottish cohorts
found no decreased mortality risk for reducers (HR, 0.98;
95 % CI, 0.85–1.13) [50].
There is also mixed evidence on whether smoking re-
duction decreases the risk of lung cancer. A systematic
review found three papers, of which the largest study
found a reduction in the risk of lung cancer in reducers
compared with maintainers [47]. A subsequent study
found no evidence of a reduction (HR, 0.91; 95 % CI,
0.70–1.19) [50]. There is convincing evidence that short-
term reductions do decrease the levels of various bio-
logical markers of carcinogen exposure or cancer-related
changes [47], but the significance for reduced risk is
unclear.
Only one study has examined the risk of admission to
hospital with COPD exacerbation in relation to reduced
exposure and found an HR of 0.93 (95 % CI, 0.73–1.18)
[51]. There is clear evidence indicating that reduced
smoking decreases COPD and asthma symptoms but
not lung function [47].
The interpretation of epidemiological data related to
the health benefits of smoking reduction is complex due
to three key issues. Firstly, most epidemiological studies
measure smoking on two occasions only but make the
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implicit assumption that smoking reduction measured at
the second occasion has been maintained for the entire
duration of follow-up. This is problematic since it is
clear that smokers experience several phases of trying to
reduce then reverting and therefore this reduced con-
sumption may not have been maintained for long. In-
deed, data indicates that, from smokers seeking to
reduce, approximately 10 % can maintain a reduced con-
sumption for 2 years [52]. Secondly, few studies have
used biomarkers of exposure. It is therefore unclear
whether those who reduce their smoking frequency and
partially compensate by smoking each cigarette more
intensively go on to adjust in the long-term [52]. In
these cases, the health benefits of reduction would not
be as great as might be predicted from the known dose-
response relation. Thirdly, all of these studies have in-
cluded smokers who have reduced without the use of
concurrent nicotine. Laboratory data show that, even at
high doses, NRT with concomitant smoking has fewer
acute effects on biomarkers of cardiovascular risk com-
pared with smoking alone in the short term [53]. The
only available long-term studies assessing the health
consequences of concurrent use of nicotine and smoked
tobacco concern snus; a systematic review of 21 relevant
studies found that, in most, the evidence suggested
that dual use was associated with reduced risks of all
smoking-related conditions compared with smoking
alone [54]. However, these studies were not formally
statistically combined and, since the benefits were
modest and studies small, few risks were individually
statistically significant.
Summary
Smokers who are unable or unwilling to quit would
benefit from a gradual reduction in the number of daily
cigarettes smoked given its benefit in the likelihood of
achieving cessation. Combining reduction attempts with
clean nicotine leads to greater reduction and cessation
rates. Indeed, e-cigarettes show particular promise since
they appeal to smokers and may help them achieve ces-
sation. Nevertheless, their rapid evolution, with newer
models outpacing older devices tested in currently pub-
lished efficacy trials, presents a challenge for researchers
and clinicians. Finally, evidence that reduced smoking
decreases the harm from smoking is suggestive, but not
conclusive. The lack of detailed characterisation of the
extent and length of smoking reduction in relation to
health outcomes makes it difficult to determine the
health benefits. Given the uncertainty of this evidence
and the clear benefits of total smoking cessation, the
focus in harm reduction should remain on promoting
cessation through reduction rather than on reduction as
an end goal.
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